Mauna Kea Technologies Appoints Deputy CEO and Chief Financial Officer

Mauna Kea Technologies, inventor of Cellvizio, the multidisciplinary confocal laser endomicroscopy platform, has appointed Olivier Regnard as deputy CEO and chief financial officer (CFO), effective immediately. Regnard brings nearly 20 years of finance, accounting and operational experience to the company and already has familiarity with Mauna Kea Technologies, having served as a consultant to the firm. In his role, Regnard will directly oversee finance, administration, information technology, human resources, and operations on a worldwide basis.
 
Prior to joining Mauna Kea Technologies, Regnard served as deputy CEO and CFO at Latécoère, a Euronext Paris-listed player in the aeronautics industry with approximately 700 million euros in annual revenue and more than 5,000 employees. During his tenure at Latécoère, Regnard was a key contributor to the implementation of the company’s strategic turn-around plan and led a financial restructuring that included 280 million euros in capital increase and 278 million euros in debt reduction. Prior to joining Latécoère, Regnard spent nearly 15 years at Deloitte, first in auditing, then in transaction services and finally in the reorganization services. Regnard graduated from ESSEC Business School in France and is a certified accountant.
 
“Since I joined the company, I have been able to fully appreciate the growth potential associated with our unique Cellvizio platform,” declared Regnard. “The progress realized in the past 24 months by the company on key success factors such as clinical data, regulatory approvals, reimbursement, as well as the strategic choice to move to a consignment business model in the U.S., has uniquely positioned Mauna Kea for success. I am excited to join the executive team at this important stage in the company’s development.”
 
Sacha Loiseau, Ph.D., founder and CEO of Mauna Kea Technologies, commented, “Since joining the company, Olivier has demonstrated strong leadership and has already contributed to the operational and financial improvement of the business. I am very pleased to welcome Olivier as deputy CEO and CFO as we continue to strengthen the company to execute on our growth strategies.”
 
Mauna Kea Technologies is a global medical device company focused on eliminating uncertainties related to the diagnosis and treatment of cancer and other diseases thanks to real time in vivo microscopic visualization. The company’s flagship product, Cellvizio, has received clearance to sell a wide range of applications in more than 40 countries, including the United States, Europe, Japan, China, Canada, Brazil and Mexico. Mauna Kea is based in Paris, France.